O ral busulfan (BU) and intravenous cycloa a phosphamide (CY) are standard conditiona a ing chemotherapeutic agents for allogeneic hematopoietic stem cell transplantation (HSCT) in thalassemic patients. 1 Pharmacokinetic studies of oral BU demonstrate wide intera and intraindividual varia a ability in drug levels. 2, 3 The association between steadya state plasma concentrations and areaaunderatheacurve (AUC) values for busulfan and the occurrence of graft failure, venoaocclusive disease (VOD), and early mora a tality have been reported. 4a6 Graft rejection is a coma a mon adverse event found in thalassemic patients una a dergoing HSCT. 1, 7 The unpredictability of busulfan levels may further increase the high incidence of graft rejection known to occur in patients with thalassemia. The use of intravenous busulfan (IVBU) may overa a come the variability of plasma drug levels leading to increased favorable outcomes after HSCT. Andersson et al 8 initially showed consistent AUCs of IVBU in adults with hematologic malignancies without increasa a ing side effects. Nguyen et al 9 demonstrated that fixed dosing based on the actual weight of pediatric patients is well correlated with targeted AUC values. With these recommended dosages, IVBU can be successfully used without therapeutic drug monitoring. 10 These data may enable clinicians to use IVBU conveniently in centers where pharmacokinetic studies can not be performed. Therefore, this study is intended to explore the efficacy and toxicity of IVBU as a part of a conditioning regia a men in thalassemic children undergoing HSC T witha a out drug monitoring.
PATIENTS AND METHODS
We analyzed children diagnosed with homozygous betaathalassemia (β/β) and betaathalassemia/Hb E The conditioning regimen consisted of IVBU every 6 hours on day -9 to -6 and intravenous CY 50 mg/ kg daily on day -5 to -2. The dosages of IVBU were adjusted based on body weight as follows: 1.0 mg/kg for <9 kg; 1.2 mg/kg for 9 to <16 kg; 1.1 mg/kg for 16a23 kg; 0.95 mg/kg for >23 to 34 kg; 0.8 mg/kg for >34 kg. Oral phenytoin was given for seizure proa a phylaxis during day a10 to a6. Intravenous fludarabine and Fresenius antithymocyte globulin (ATG) were added for patients who received stem cells from an unrelated donor. Graft versus host disease (GVHD) prophylaxis consisted of intravenous cyclosporine A (CsA) 1.5 mg/kg every 12 hours starting day a 2 and intravenous methotrexate 5 mg/m 2 on day +1, +3, +6, and +11. The intravenous CsA was changed to the oral form when the patients could tolerate oral media a cations. The CsA was administered until day +150, and then tapered and discontinued over 30 days, if the patient had no evidence of GVHD. The CsA level was maintained between 200 and 300 ng/mL. Daily intravenous GaCSF 5 mcg/kg was started on day +1 and discontinued after neutrophil engraftment was documented. Acute GVHD grading and the severa a ity of chronic GVHD were analyzed as previously described. 11, 12 The severity of adverse side effects were graded according to the National Cancer Institute's common toxicity criteria version 2.0.
13 Hepatic VOD was diagnosed and classified into mild, moderate, and severe as described by McDonald et al.
an absolute neutrophil count (ANC) more than 500/ mm 3 and platelet count more than 20 000/mm 3 for 3 consecutive days without platelet support, respectively. Chimerism status was studied by using fluorescence in situ hybridization of Y chromosome and short tana a dem repeat DNA study of peripheral blood leukocytes in sexamismatched and sexamatched donorarecipient pairs, respectively. The evaluation of donor chimerism was scheduled on day +28, +60, +120, +180 and at the end of the first year after transplantation. If there is clinical suspicion or laboratory evidence of graft rejeca a tion, chimerism status was checked more frequently.
RESULTS
Ten patients with median age of 6 years (range, 1.9a8.4 years) were treated with IVBUCY regimen during this study period (Table 1 ). The median followaup time was 13 months (range 5a18) months. The patients received stem cells from sibling bone marrows (n=8), cord blood (n=1), and unrelated bone marrow (n=1). The mea a dian CD34+ cells in the grafts were 8.03×10
6 cells/kg (range, 0.32a14.76×10 6 cells/kg). The time to neutroa a phil engraftment range was 11 to 20 days (median 14.5 days) and platelet engraftment range was 19 to 28 days (median 25 days). All the patients engrafted with full Mild mucositis (Grade IaII) was found in 2 patients only and Grade IIaIII enteritis in 4 patients. Mild and moderate hepatic VOD was diagnosed in 5 patients. The VOD resolved with fluid restriction, diuretics, and dopamine. Acute GVHD Grade I of skin occurred in 2 patients and limited chronic GVHD in 3 patients. Patient no. 1 and 9 suffered from BK virus associated hemorrhagic cystitis on day +98 and +9, respectively. Patient (no. 10) had adenovirusaassociated hematuria on day +8. However, all three patients were successfully treated with aggressive hydration.
DISCUSSION
Pharmacokinetic studies of IVBU have shown the bena a efits over oral BU in terms of consistent plasma concena a trations and AUC levels as well as administrative cona a venience. 8, 9 Recently, Vassel et al 10 have recommended fixed doses of IVBU according to body weight in pea a diatric age, and this resulted in satisfactory AUC levels even without drug monitoring. The authors performed a retrospective pharmacokinetic study in 55 patients with various diseases receiving autologous and allogea a neic HSCT. Over 80% of AUCs of the patients were within the therapeutic window. No patient experienced a subatherapeutic AUC, which is important for diseases with a high incidence of graft failure such as thalassea a mia. Therefore, IVBU with these recommended doses temped us to change the usage of oral to IV form.
Our retrospective analysis of a homogenous group of thalassemic children confirmed the efficacy of using IVBU without the need for a pharmacokinetic study. All patients achieved full donor engraftment at 2 months afa a ter HSCT, which predicts the sustained longaterm stable chimerism in thalassemic patients. 1 However, we have no patient with class 3 who is expected to have adverse outcome after HSCT.
1 Therefore, the efficacy of IVBU in this group of patients needs further exploration.
The transplant related toxicity after HSCT was mild and manageable. The common side effects of IVBU were stomatitis and enteritis, as reported in other studies. 10, 15 The hepatic VOD was higher than in previous reports using IVBU in pediatric patients. 10, 15, 16 This finding may need to be confirmed in a larger group of patients. Additionally, the difference of genetic polymorphism in glutatione Satransferase M1 among ethnicities may ina a fluence the risk of hepatic VOD after HSCT. 17 In conclusion, this study supports for the safety and efficacy of IVBU usage without drug monitoring in children. IVBU may reduce the risk of graft failure or mixed chimerism in thalassemic patients because of its consistent and predictable drug levels. A future study of IVBU in higharisk thalassemic patients is warranted.
